Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

por Munster, P N, Marchion, D, Thomas, S, Egorin, M, Minton, S, Springett, G, Lee, J-H, Simon, G, Chiappori, A, Sullivan, D, Daud, A
Publicado 2009

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

por Munster, P N, Thurn, K T, Thomas, S, Raha, P, Lacevic, M, Miller, A, Melisko, M, Ismail-Khan, R, Rugo, H, Moasser, M, Minton, S E
Publicado 2011

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

por Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Publicado 2012